Renaissance Technologies’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15.3M Sell
445,000
-68,578
-13% -$2.07M 0.02% 837
2026
Q1
$12.2M Buy
513,578
+357,078
+228% +$9.91M 0.02% 868
2025
Q4
$4.34M Buy
+156,500
New +$3.99M 0.01% 1386
2025
Q2
Sell
-12,107
Closed -$236K 3558
2025
Q1
$236K Sell
12,107
-10,800
-47% -$283K ﹤0.01% 3018
2024
Q4
$568K Buy
+22,907
New +$585K ﹤0.01% 2783
2023
Q1
Sell
-131,900
Closed -$5.16M 3977
2022
Q4
$5.16M Buy
131,900
+60,600
+85% +$2.71M 0.01% 1506
2022
Q3
$3.4M Sell
71,300
-208,600
-75% -$11.9M ﹤0.01% 1685
2022
Q2
$10.8M Buy
+279,900
New +$11.1M 0.01% 1072
2021
Q3
Sell
-16,500
Closed -$2.12M 3475
2021
Q2
$2.12M Sell
16,500
-21,600
-57% -$1.72M ﹤0.01% 2217
2021
Q1
$3.05M Buy
+38,100
New +$3.62M ﹤0.01% 1955

Other funds holding BEAM

Renaissance Technologies's BEAM Position: Q2 2026 in Review

Renaissance Technologies reduced its Beam Therapeutics (BEAM) stake by 13% in Q2 2026, selling an estimated $2.07M and leaving 445,000 shares worth $15.3M. The position accounts for 0.02% of the portfolio, ranked #837.

Renaissance Technologies first reported a position in BEAM in Q1 2021 and has held it in 10 quarters since. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Renaissance Technologies held 445,000 shares of Beam Therapeutics worth $15.3M as of Q2 2026.
  • Renaissance Technologies sold 68,578 Beam Therapeutics shares in Q2 2026, an estimated $2.07M.
  • Beam Therapeutics made up 0.02% of Renaissance Technologies's portfolio in Q2 2026, its #837 holding.
  • Renaissance Technologies first reported a position in Beam Therapeutics in Q1 2021 and has held it in 10 quarters since.
  • 278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.